MedTrace Logo

Therapeutic Role of Transcranial DCS in Alzheimer

NCT03313518 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-10-18

No results posted yet for this study

Summary

The aim of this study is to evaluate the oxidative stress and brain damage biomarkers induced by tDCS in patients with AD and to assess the long term neurophysiological and behavioral effects after repeated daily tDCS sessions for 10 days. Thirty AD patients diagnosed according to 2011 McKhann criteria will be randomly assigned to receive 10 real anodal tDCS or sham at 2mA intensity for 20 minutes per session daily. All patients will be evaluated at baseline, at the end of the sessions and 1, 2, and 3 months later with neurophysiological and behavioral examination.

Conditions

  • Alzheimer Disease

Interventions

DEVICE

tDCS

15 patients received real anodal tDCS for 20 minutes daily for 10 consecutive days.

DEVICE

Sham tDCS

15 patients received sham anodal tDCS for 20 minutes daily for 10 consecutive days.

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Eman M. Khedr, MD · Professor of Neurology, Faculty of Medicine, Assiut University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-12
Primary Completion
2017-10-10
Completion
2017-10-10

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03313518 on ClinicalTrials.gov